These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 27746322)

  • 1. Genetic diseases resulting from disordered FGF23/klotho biology.
    Econs MJ
    Bone; 2017 Jul; 100():56-61. PubMed ID: 27746322
    [No Abstract]   [Full Text] [Related]  

  • 2. Miscellaneous non-inflammatory musculoskeletal conditions. Hyperphosphatemic familial tumoral calcinosis (FGF23, GALNT3 and αKlotho).
    Farrow EG; Imel EA; White KE
    Best Pract Res Clin Rheumatol; 2011 Oct; 25(5):735-47. PubMed ID: 22142751
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A homozygous missense mutation in human KLOTHO causes severe tumoral calcinosis.
    Ichikawa S; Imel EA; Kreiter ML; Yu X; Mackenzie DS; Sorenson AH; Goetz R; Mohammadi M; White KE; Econs MJ
    J Musculoskelet Neuronal Interact; 2007; 7(4):318-9. PubMed ID: 18094491
    [No Abstract]   [Full Text] [Related]  

  • 4. Hyperphosphatemic familial tumoral calcinosis: genetic models of deficient FGF23 action.
    Folsom LJ; Imel EA
    Curr Osteoporos Rep; 2015 Apr; 13(2):78-87. PubMed ID: 25656441
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A homozygous missense mutation in human KLOTHO causes severe tumoral calcinosis.
    Ichikawa S; Imel EA; Kreiter ML; Yu X; Mackenzie DS; Sorenson AH; Goetz R; Mohammadi M; White KE; Econs MJ
    J Clin Invest; 2007 Sep; 117(9):2684-91. PubMed ID: 17710231
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ablation of the Galnt3 gene leads to low-circulating intact fibroblast growth factor 23 (Fgf23) concentrations and hyperphosphatemia despite increased Fgf23 expression.
    Ichikawa S; Sorenson AH; Austin AM; Mackenzie DS; Fritz TA; Moh A; Hui SL; Econs MJ
    Endocrinology; 2009 Jun; 150(6):2543-50. PubMed ID: 19213845
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phenotypic and Genotypic Characterization and Treatment of a Cohort With Familial Tumoral Calcinosis/Hyperostosis-Hyperphosphatemia Syndrome.
    Ramnitz MS; Gourh P; Goldbach-Mansky R; Wodajo F; Ichikawa S; Econs MJ; White KE; Molinolo A; Chen MY; Heller T; Del Rivero J; Seo-Mayer P; Arabshahi B; Jackson MB; Hatab S; McCarthy E; Guthrie LC; Brillante BA; Gafni RI; Collins MT
    J Bone Miner Res; 2016 Oct; 31(10):1845-1854. PubMed ID: 27164190
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An FGF23 missense mutation causes familial tumoral calcinosis with hyperphosphatemia.
    Benet-Pagès A; Orlik P; Strom TM; Lorenz-Depiereux B
    Hum Mol Genet; 2005 Feb; 14(3):385-90. PubMed ID: 15590700
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Congenital Hyperphosphatemic Conditions Caused by the Deficient Activity of FGF23.
    Ito N; Fukumoto S
    Calcif Tissue Int; 2021 Jan; 108(1):104-115. PubMed ID: 31965220
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dialysis as a Treatment Option for a Patient With Normal Kidney Function and Familial Tumoral Calcinosis Due to a Compound Heterozygous FGF23 Mutation.
    Goldenstein PT; Neves PD; Balbo BE; Elias RM; Pereira AC; Onuchic LF; Jüppner H; Jorgetti V; Abensur H; Moysés RM
    Am J Kidney Dis; 2018 Sep; 72(3):457-461. PubMed ID: 29548779
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Familial tumoral calcinosis and the role of O-glycosylation in the maintenance of phosphate homeostasis.
    Chefetz I; Sprecher E
    Biochim Biophys Acta; 2009 Sep; 1792(9):847-52. PubMed ID: 19013236
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tumoral calcinosis presenting with eyelid calcifications due to novel missense mutations in the glycosyl transferase domain of the GALNT3 gene.
    Ichikawa S; Imel EA; Sorenson AH; Severe R; Knudson P; Harris GJ; Shaker JL; Econs MJ
    J Clin Endocrinol Metab; 2006 Nov; 91(11):4472-5. PubMed ID: 16940445
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Familial tumoral calcinosis: from characterization of a rare phenotype to the pathogenesis of ectopic calcification.
    Sprecher E
    J Invest Dermatol; 2010 Mar; 130(3):652-60. PubMed ID: 19865099
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A novel recessive mutation of fibroblast growth factor-23 in tumoral calcinosis.
    Masi L; Gozzini A; Franchi A; Campanacci D; Amedei A; Falchetti A; Franceschelli F; Marcucci G; Tanini A; Capanna R; Brandi ML
    J Bone Joint Surg Am; 2009 May; 91(5):1190-8. PubMed ID: 19411468
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A case of familial tumoral calcinosis/hyperostosis-hyperphosphatemia syndrome due to a compound heterozygous mutation in GALNT3 demonstrating new phenotypic features.
    Dumitrescu CE; Kelly MH; Khosravi A; Hart TC; Brahim J; White KE; Farrow EG; Nathan MH; Murphey MD; Collins MT
    Osteoporos Int; 2009 Jul; 20(7):1273-8. PubMed ID: 18982401
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A novel homozygous missense mutation in FGF23 causes Familial Tumoral Calcinosis associated with disseminated visceral calcification.
    Chefetz I; Heller R; Galli-Tsinopoulou A; Richard G; Wollnik B; Indelman M; Koerber F; Topaz O; Bergman R; Sprecher E; Schoenau E
    Hum Genet; 2005 Nov; 118(2):261-6. PubMed ID: 16151858
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hyperphosphatemic familial tumoral calcinosis secondary to fibroblast growth factor 23 (FGF23) mutation: a report of two affected families and review of the literature.
    Chakhtoura M; Ramnitz MS; Khoury N; Nemer G; Shabb N; Abchee A; Berberi A; Hourani M; Collins M; Ichikawa S; El Hajj Fuleihan G
    Osteoporos Int; 2018 Sep; 29(9):1987-2009. PubMed ID: 29923062
    [TBL] [Abstract][Full Text] [Related]  

  • 18. FGF23 Is Not Required to Regulate Fetal Phosphorus Metabolism but Exerts Effects Within 12 Hours After Birth.
    Ma Y; Kirby BJ; Fairbridge NA; Karaplis AC; Lanske B; Kovacs CS
    Endocrinology; 2017 Feb; 158(2):252-263. PubMed ID: 27929669
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Familial tumoral calcinosis caused by a novel FGF23 mutation: response to induction of tubular renal acidosis with acetazolamide and the non-calcium phosphate binder sevelamer.
    Lammoglia JJ; Mericq V
    Horm Res; 2009; 71(3):178-84. PubMed ID: 19188744
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Severe vascular calcification and tumoral calcinosis in a family with hyperphosphatemia: a fibroblast growth factor 23 mutation identified by exome sequencing.
    Shah A; Miller CJ; Nast CC; Adams MD; Truitt B; Tayek JA; Tong L; Mehtani P; Monteon F; Sedor JR; Clinkenbeard EL; White K; Mehrotra R; LaPage J; Dickson P; Adler SG; Iyengar SK
    Nephrol Dial Transplant; 2014 Dec; 29(12):2235-43. PubMed ID: 25378588
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.